5-Amino-1MQ is a small-molecule NNMT inhibitor researched for its potential role in regulating energy balance, metabolic function, and adiposity. While the compound is also available in lyophilized powder form for
BPC-157 + TB-500 20mg Blend
$105.00BPC-157 (Body Protection Compound-157) and TB-500 (synthetic thymosin beta-4) are two peptides commonly studied in experimental models for their roles in tissue repair and regeneration. While both compounds have distinct
The CJC-1295 (No DAC) + Ipamorelin Blend represents a dual-pathway approach to growth hormone (GH) modulation, combining the upstream stimulation of growth hormone–releasing hormone (GHRH) receptors with the downstream activation
GLOW 70mg Blend
$160.00This multi-peptide preparation unites three widely researched regenerative peptides into a single vial for investigations that probe complementary pathways of tissue repair and remodeling.- GHK-Cu is best known for up-regulating
MOTS-c 40mg
$148.00MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16–amino-acid peptide encoded within the mitochondrial 12S rRNA gene region. It belongs to the family of mitochondrial-derived
Reta (GLP-3) 20mg
$195.00Retatrutide is an investigational multi-agonist peptide engineered to activate three metabolic hormone receptors—GLP-1, GIP, and glucagon—positioning it as a next-generation “triple agonist.” In research settings, it has been
Sema (GLP-1) 20mg
$115.00Semaglutide is a long-acting GLP-1 receptor agonist (GLP-1RA) investigated for its effects on glycemic regulation and body-weight–related outcomes in controlled research settings. It is structurally optimized for extended
Tesamorelin + Ipamorelin is a dual-pathway growth hormone research blend combining a stabilized GHRH analog with a selective growth hormone secretagogue (GHS). Tesamorelin stimulates growth hormone release through GHRH receptor
Tirz (GLP-2) 20mg
$150.00Tirzepatide is a long-acting synthetic polypeptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating both incretin pathways, it has been
